Form 4: Salarius Pharmaceuticals CEO Receives Stock Grant
Insider Transaction (Form 4)
Frederick Pierce Ii, Chief Executive Officer of Salarius Pharmaceuticals, Inc., received 33,455 shares of common stock on August 31, 2026.
Summary
- Grant/award: acquired 33,455 Common Stock on August 31, 2026; holds 34,844 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Frederick Pierce Ii — Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-31 | Grant/award | Common Stock | 33,455 | — | — | 34,844 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-31 | Grant/award (33,455 shares) |
Keywords
insider transaction, Form 4, DCOY, Decoy Therapeutics Inc., neutral, Frederick Pierce Ii
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.